Fusen Pharmaceutical Company Limited (HKG:1652)
Hong Kong · Delayed Price · Currency is HKD 0.8300
-0.0100 (-1.19%)
Sep 18, 2026, 3:59 PM HKT
HKG:1652 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 276.14 | 273.37 | 326.03 | 565.61 | 491.76 | 385.66 | |
Revenue Growth | 14.58% | -16.15% | -42.36% | 15.02% | 27.51% | -20.78% |
Cost of Revenue | 160.22 | 163.58 | 163.39 | 266.1 | 266.74 | 174.53 |
Gross Profit | 115.92 | 109.79 | 162.64 | 299.51 | 225.02 | 211.13 |
Selling, General & Admin | 83.73 | 97.12 | 132.2 | 214.44 | 173.47 | 156.18 |
Research & Development | 6.91 | 13.29 | 106.26 | 65.2 | 15.18 | - |
Other Operating Expenses | -19.88 | -17.44 | -17.73 | -1.58 | -9.03 | -10.97 |
Operating Expenses | 110.55 | 118.91 | 229.81 | 278.05 | 179.61 | 145.22 |
Operating Income | 5.37 | -9.12 | -67.18 | 21.45 | 45.41 | 65.92 |
Interest Expense | -20.9 | -20.36 | -20.14 | -12.58 | -12.38 | -8.24 |
Interest & Investment Income | 0.09 | 0.02 | 0.02 | 0.42 | 1.97 | 2.56 |
Earnings From Equity Investments | 9.59 | 14.45 | -104.1 | -40.62 | -21.02 | -1.97 |
Currency Exchange Gain (Loss) | - | - | 1.28 | 3.32 | -5.32 | -1.41 |
EBT Excluding Unusual Items | -5.85 | -15 | -190.11 | -28.01 | 8.67 | 56.85 |
Gain (Loss) on Sale of Investments | 0.59 | 0.59 | -0.34 | -0.31 | -37.99 | -21.02 |
Gain (Loss) on Sale of Assets | 6.81 | 6.81 | 0 | -1.12 | -1.67 | -12.04 |
Pretax Income | 1.55 | -7.6 | -190.45 | -29.45 | -30.99 | 23.79 |
Income Tax Expense | 3.89 | 4.2 | -1.65 | 6.85 | 3.66 | 7.18 |
Earnings From Continuing Operations | -2.34 | -11.8 | -188.8 | -36.3 | -34.65 | 16.61 |
Minority Interest in Earnings | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.03 |
Net Income | -2.32 | -11.78 | -188.78 | -36.28 | -34.61 | 16.65 |
Net Income to Common | -2.32 | -11.78 | -188.78 | -36.28 | -34.61 | 16.65 |
Net Income Growth | - | - | - | - | - | -76.27% |
Shares Outstanding (Basic) | 741 | 739 | 740 | 752 | 756 | 770 |
Shares Outstanding (Diluted) | 741 | 739 | 740 | 752 | 756 | 770 |
Shares Change | 0.27% | -0.09% | -1.60% | -0.53% | -1.85% | -2.51% |
EPS (Basic) | -0.00 | -0.02 | -0.26 | -0.05 | -0.05 | 0.02 |
EPS (Diluted) | -0.00 | -0.02 | -0.26 | -0.05 | -0.05 | 0.02 |
EPS Growth | - | - | - | - | - | -77.58% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 71.82 | 72.77 | -86.42 | 86.63 | -62.37 |
Free Cash Flow Per Share | - | 0.10 | 0.10 | -0.12 | 0.12 | -0.08 |
Dividend Per Share | - | - | - | - | - | 0.009 |
Dividend Growth | - | - | - | - | - | 0% |
Gross Margin | 41.98% | 40.16% | 49.88% | 52.95% | 45.76% | 54.74% |
Operating Margin | 1.94% | -3.34% | -20.60% | 3.79% | 9.23% | 17.09% |
Profit Margin | -0.84% | -4.31% | -57.90% | -6.41% | -7.04% | 4.32% |
Free Cash Flow Margin | - | 26.27% | 22.32% | -15.28% | 17.62% | -16.17% |
EBITDA | 33.8 | 23.32 | -32.52 | 49.56 | 72.33 | 83.35 |
EBITDA Margin | 12.24% | 8.53% | -9.98% | 8.76% | 14.71% | 21.61% |
D&A For EBITDA | 28.43 | 32.45 | 34.65 | 28.1 | 26.92 | 17.43 |
EBIT | 5.37 | -9.12 | -67.18 | 21.45 | 45.41 | 65.92 |
EBIT Margin | 1.94% | -3.34% | -20.60% | 3.79% | 9.23% | 17.09% |
Effective Tax Rate | 251.10% | - | - | - | - | 30.17% |